LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Summary

The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.

Timeline

Start

2023-02-27

Primary completion

2024-12-26

Completion

2029-01

Publications

• Li T, Feng J, Yang X, Yang S, Chen J, Wu Y, Li X, Ni Z, Liu Y, Song M, Huang P, Zheng K, Wang H, Xu X, Sun J, Wang F, Jia H, Sun X. Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results. Cell Rep Med. 2026 Jun 12:102869. doi: 10.1016/j.xcrm.2026.102869. Online ahead of print.

Drugs

Indications